Research programme: human papillomavirus vaccine - Crucell/Ortho-McNeil-Janssen

Drug Profile

Research programme: human papillomavirus vaccine - Crucell/Ortho-McNeil-Janssen

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell; Ortho-McNeil-Janssen Pharmaceuticals
  • Developer Crucell; Janssen Pharmaceuticals
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Human papillomavirus infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Human-papillomavirus-infections in Netherlands
  • 22 Feb 2011 Crucell has been acquired by Johnson & Johnson
  • 09 Nov 2010 Early research in Human papillomavirus infections in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top